Wegovy reduced deaths from Covid-19?

SELECT trial post hoc reveals surprising knock-on benefit from semaglutide

In the SELECT trial, semaglutide (Wegovy and Ozempic’s active ingredient) reduced cardiovascular death and all-cause mortality among 17,604 enrolled patients—an impressive finding that revealed the drug’s potential not just for weight loss, but for control of chronic diseases associated with obesity.

But wait, there’s more.

When the coronavirus pandemic s…